[ad_1] Glenmark Pharmaceuticals It said on Saturday that its consolidated profit after tax declined 26 per cent to Rs 173 crore for the fourth quarter ended March 31, 2022. The company had reported profit after tax (PAT) of Rs 234 crore in the January-March period of 2020-21 financials. However, the pharmaceutical firm’s consolidated revenue rose to Rs 3,019 crore in the quarter under review from Rs 2,860 crore in the year-ago period, registering a year-on-year growth of 6 per cent. For the year ended March 31, 2022, the Mumbai-based pharmaceutical…